<DOC>
	<DOCNO>NCT01254136</DOCNO>
	<brief_summary>This Phase I/II study design assess safety therapeutic effect INCB007839 combination trastuzumab vinorelbine patient metastatic HER2+ breast cancer .</brief_summary>
	<brief_title>Safety Efficacy INCB007839 With Trastuzumab Vinorelbine Patients With Metastatic HER2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Subject diagnosis metastatic ( locally recurrentinoperable ) breast cancer Subject histological HER2+ status determine FISH gene amplification score â‰¥ 2.2 Subject availability archival biopsy tissue primary tumor metastatic lesion Subject presence measurable disease base RECIST 1.1 Subject receive three prior HER2directed therapeutic regimen advance breast cancer Subject Left ventricular ejection fraction ( LVEF ) institutional normal range Subject metastasis central nervous system UNLESS asymptomatic clinically stable Subject current active malignancy breast cancer Subject prior history malignancy except cancer patient currently disease free Subject significant renal hepatic dysfunction Subject history venous arterial thrombosis risk factor thrombosis history malignancy Subject insufficient bone marrow function Subject contraindication vinorelbine , trastuzumab , aspirin and/or warfarin therapy . Subject current active bacterial , Hepatitis B C , and/or HIV infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>